#AANAM – Opicapone Can Prolong ‘On-Time’ Levopoda Provides, Data from Phase 3 Trials Show

#AANAM – Opicapone Can Prolong ‘On-Time’ Levopoda Provides, Data from Phase 3 Trials Show
Once-daily opicapone can prolong the time during which treatment with levopoda, a standard therapy, effectively prevents motor symptom fluctuations in people with Parkinson’s disease, results from two international Phase 3 studies show. The findings, “Once-Daily Opicapone Increases ON-Time in Patients with Parkinson’s Disease: Results from Two Phase 3 Studies,” were presented during the 2019 Annual Meeting of the American Academy of Neurology (AAN), now ... read more
Source: Parkinson’s News TodayPublished on 2019-05-06By Alice Melão